Applications of Theranostics for Detecting and Targeting CNS Injuries and Diseases

<jats:p />

As of today, the limit of medical science is the inability to efficiently and completely eliminate neuronal damage caused by secondary insult from neurological trauma and neurodegenerative diseases. In general, the primary insult occurs at the time of impact; it involves contusions, lacerations, and axonal injury as a result of shearing, tearing, or stretching with consequent impairment of the neural architecture. Initial traumatic injuries or pathogen-associated molecular patterns (PAMPs) from misfolded proteins evoke secondary insult by virtue of dynamic interactions among ischemic, inflammatory, cytotoxic processes, and mitochondrial dysfunction [1]. These types of molecular-level elements that may contribute to the holistic scale are implicated in the pathogenesis of neuro-oncology. Impaired immune competence, such as dysregulation of macrophages and microglia, and mitochondrial dysfunction reciprocally impact the microenvironment of glioblastoma and its prognosis [2]. As such, the future perspectives are to ensure the detection of disease at an extremely early stage through advanced diagnostic methods or to salvage primary lesions via advanced surgical interventions and, most fundamentally, to prevent widespread secondary injuries by exploring the microscopic pathogenesis or through interventions on a molecular level, which will be the objective and mission of the scientific community in the coming years.
Following a meticulous peer review process, we have decided to include 12 manuscripts in this special issue, composed of 11 research and 1 review article. In the clinical context, olfactory impairment is being recognized as a marker for the early detection of cognitive decline and Alzheimer's disease (AD) dementia. The transport pathways of olfactory signals superimpose substantially with those of dopamine and 5-hydroxytryptamine. Structural and physical dysfunction between the brain areas involved leads to dysregulated neurotransmission and accordingly to impaired olfaction [3]. Beyond olfactory dysfunction, X. Mei et al. indicated that amyloid β (Aβ) levels in the mouse retina corresponded to Aβ amounts in the brain; the appropriate time to measure retinal Aβ deserves emphasis. Moreover, Professor A. C. W. Huang et al. found in posttraumatic stress disorder (PTSD) animals a subtle affiliation of brain-derived neurotrophic factor (BDNF) expression in the medial prefrontal cortex (mPFC), amygdala, and hippocampus during situational reminders, whereas fluoxetine, a class of specific 5-hydroxytryptamine reuptake inhibitor drugs, was effective only on the basal amygdale, but not on the mPFC. The interconnections and pathogenesis of these complex neural structures need to be further understood in the setting of neurodegenerative diseases.
Early The implementation of artificial intelligence technology assists in early detection, shortens the period of diagnosis, and forecasts the outcome of the disease. Z.-Q. Pan et al. display that machine learning-based radiomic features (tumour shape, intensity, and texture) can predict the response to radiotherapy in patients with glioblastomas. Professor J. Jiang et al. introduced a metabolic connectome-based predictive model for 18 F-fluorodeoxyglucose-(FDG-) PET images to facilitate the identification of brain metabolic dysfunction and established a clinically applicable biomarker to predict the progression of mild cognitive impairment to AD.
Upstream blockage of molecular pathogenic mechanisms contributes to the repression of disease advancement. In their review, T. Pi et al. underlined that the environmental factor, homocysteine, has mediated DNA methylation and contributes to the development of AD. CDGSH iron-sulfur structural domain 2 (CISD2) exerted anti-inflammatory effects by functioning as an upstream regulatory constituent of the PPAR-β/NF-κB signal through the findings of M.-S. Lin et al. The anti-inflammatory natural compound wild bitter melon (WBM) showed a modulatory effect on CISD2 expression in injured animals and cells. This protective protein, CISD2, holds high potential as a target for the treatment of injury and disease in the central nervous system (CNS) [4].
Ultimately, we expect the endeavors of the authors to generate multidisciplinary viewpoints and novel insights that will achieve further advances in the domain of CNS injury and disease.

Conflicts of Interest
I declare that we have no conflict of interest or private agreements with companies concerning the manuscripts in this special issue.